Quadient Recognized in Analyst Report on Top AI Use Cases for Finance Automation

Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, announces it has been recognized in a recent Forrester report on ways artificial intelligence (AI) is transforming accounts receivable (AR) processes. The report, 'Top AI Use Cases for Accounts Receivable Automation In 2025,' includes mentions of Quadient AR for cash application and payment notice. Quadient considers its inclusion in the report as proof of the impact its AI- and machine learning-powered financial process automation offer, enhancing efficiency, accuracy, and decision-making capabilities.
Manual AR, AP and invoice processes lead to inefficiencies, compliance risks, payment delays and increased vulnerability to fraud. Quadient's Finance Automation cloud platform, including Quadient AR and Quadient AP, addresses these challenges, using advanced AI and machine learning to predict cash flow with high accuracy, analyze payor behavior, and automate cash applications, even when remittance data is missing. The platform also centralizes invoices and streamlines multi-channel distribution, ensuring full compliance with regulations such as e-invoicing.
'AI is transforming accounts receivable, and we believe Quadient's inclusion in Forrester's report attests to how advanced solutions such as Quadient AR are changing the way financial professionals work through intelligent automation,' said Chris Hartigan, Chief Solution Officer, Digital Automation at Quadient. 'AI and machine learning are forever changing the way AR and AP are managed and increasing the value these functions bring to organizations. Quadient is helping to advance AI usage by finance teams in responsible and meaningful ways to streamline workflows, deliver actionable insights, enhance efficiency and increase focus on strategic financial planning.'
Real-time data is provided through customizable dashboards, enhancing efficiency and decision-making capabilities. In addition to mentioning Quadient in several use cases for AR, Forrester interviewed Quadient for insights for its companion report, 'Top AI Use Cases for Accounts Payable Automation in 2025.'
Quadient's leading cloud-based financial automation cloud platform, including AR, AP, e-invoicing and customer communications, helps businesses reduce manual work, improve cash flow and make more informed financial decisions.
About Quadient®Quadient is a global automation platform powering secure and sustainable business connections through digital and physical channels. Quadient supports businesses of all sizes in their digital transformation and growth journey, unlocking operational efficiency and creating meaningful customer experiences. Listed in compartment B of Euronext Paris (QDT) and part of the CAC® Mid & Small and EnterNext® Tech 40 indices, Quadient shares are eligible for PEA-PME investing. For more information about Quadient, visit http://www.quadient.com/en/.
Contacts
Sandy Armstrong, Sterling Kilgore
Joe Scolaro, Quadient
VP of Media & Communications
Global Press Relations Manager
+1-630-699-8979
+1 203-301-3673
sarmstrong@sterlingkilgore.com
j.scolaro@quadient.com
Attachment
PR Quadient Forrester Report on AI in AR

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

7 hours ago

• Business Wire

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.

Miami Herald

a day ago

• Miami Herald

Underneath the busy Baltimore streets, the Howard Street Tunnel gets its makeover

BALTIMORE - A squad of construction workers descend daily under the streets of Baltimore. They labor deep down, in the semi-secret and highly restricted chamber known as the Howard Street Tunnel. The massive brick-lined tube, hand-dug in the 1890s under the bed of downtown Baltimore's Howard Street, has been closed to freight rail traffic since February for this complex infrastructure makeover. "It's definitely a unique project," says Derek Mihaly, CSX Railroad's Mid-Atlantic director of construction who is heading the effort. The work runs 24 hours a day, seven days a week. Along the way, the tunnel got WiFi and toilets. It's an eerie and oddly cool place, no matter how hot it is upstairs. There's not a trace of graffiti and only the atmospheric smudges of a half century of locomotive coal smoke color the brick walls. It seems enormous and never-ending. It's meant for heavy business and shares nothing with a traditional highway or subway tunnel. Mihaly said that just this week, the workers achieved the 47% completion mark to lower the historic, 1895 rail tunnel by 2 feet. The tunnel is now officially lowered from Mount Royal Station near the Joseph Meyerhoff Symphony Hall to Centre Street, a spot west of the Walters Art Museum. Once this brick-lined tube is deepened and rails re-laid, it will be capable of carrying double stacks of steel shipping containers from M&T Bank Stadium to North Baltimore and a vital connection to Baltimore's Seagirt Marine Terminal Intermodal Container Facility. "We found the original tunnel in great condition," said Mihaly. One surprise, he said, was the solid rock encountered at Mount Royal Avenue. The rest of the way was the same clay you encounter when you dig a hole in and around Baltimore. He explained that his contractors built a machine for this job that clears out the base debris (the brick tunnel flooring) and then inserts a new concrete base. "That base is shaped like the bottom half of a stop sign," Mihaly said. The work is costly. The $466 million cost is shared by the State of Maryland, CSX, the Federal Railroad Administration, and the Pennsylvania Department of Transportation. Within that cost, the State of Maryland has pledged $247.5 million for the project. Several bridges will also have to be altered, including a city-owned span at Sisson Street. Pennsylvania has pledged to alter its bridges where the railroad passes. This tunnel modification will accommodate the height of double-stacked container trains and give the CSX a speedy route to the Midwest. Two construction entities are doing the work - Skanska USA (a firm founded in Sweden) and Joseph B. Fay, based in Glen Burnie. The precast concrete sections were fabricated in Chesapeake, Virginia. The tunnel passes on a north-south course through downtown Baltimore. The tracks connect Washington, Western Maryland and Philadelphia, among other destinations. Because of its port, Baltimore is a major traffic point for the railroad, founded as the Baltimore and Ohio here in 1827. The old Baltimore and Ohio Railroad built the tunnel in 1895 to get its trains to Philadelphia and Jersey City. Passenger service along this route ended in 1958, with only a summertime race fans' train bound for Delaware Park after that. But the tunnel had famous travelers. Many presidents rode this line - it was a favorite of Franklin D. Roosevelt - and Queen Elizabeth and Prince Philip in 1957. The tunnel is listed on the National Register of Historic Places and was scientifically innovative for the 1890s. It was fitted to power special electric locomotives that were attached to steam locomotives. The mighty electric engines pulled trains from Camden Station to Waverly, where they switched off and the steam locomotives pressed on to Philadelphia. Freight trains are expected to begin running later this year, Mihaly said. It may take a while longer to see the completion of a replacement bridge at Harford Road and a partially reconstructed North Avenue Bridge. The North Avenue site has several challenges. While the CSX tracks run exposed in daylight, they must pass under the bridge's stone arch and on top of another underground tube - the Amtrak and MARC train Frederick Douglass Tunnel. Persons working in downtown office buildings, or living near the Hippodrome Theatre, or riding light rail, observe no active construction activity. And yet, under some of the city's busiest streets, workers are laboring only about 40 feet away. The place to observe the staging site for the operation is in the Remington neighborhood, near West 26th and Sisson streets. On the south end, the removed clay and rock are being stored at the CSX property at Mount Winans at Gable Avenue. "From the top, there is no idea that anything is happening," said Mihaly. "And that's a good thing," he quickly adds. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.

Business Wire

2 days ago

• Business Wire

Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Bausch + Lomb Corporation ('BLCO' or the 'Company') (NYSE: BLCO) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAUSCH + LOMB CORPORATION (BLCO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On March 27, 2025, BLCO disclosed that it had '[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs)' and was voluntarily recalling all of its enVista Envy and enVista Aspire IOLs, as well as enVista monofocal lenses. On this news, BLCO's stock price fell $1.54, or 9.8%, over two consecutive trading days to close at $14.13 per share on March 28, 2025, thereby injuring investors. Then, on April 30, 2025, BLCO released its first quarter 2025 financial results, disclosing that 'as enVista ramps back up, for the full year 2025, [it] estimate[s] one-time recall headwinds of approximately $55 million to revenue and $65 million to adjusted EBITDA.' On this news, BLCO's stock price fell $2.16, or 15.7%, to close at $11.56 per share on April 30, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding BLCO should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.